Skip to main content
SpringerLink
Log in

T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis

  • Letter to the Editor
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

The Original Article was published on 05 October 2014

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kishi T, Iwata N (2014) Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-014-0551-3

  2. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, George TP (2012) A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 73(5):654–660

    Article  CAS  PubMed  Google Scholar 

  3. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL (2011) Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 129(1):94–95

    Article  PubMed Central  PubMed  Google Scholar 

  4. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37(3):660–668

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A (2011) Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 68:1195

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA (2014) Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 311(2):145–154

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Huang Y, Lewis S, Britton J (2014) Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis. BMC Public Health 14(1):1024

    Article  PubMed Central  PubMed  Google Scholar 

  8. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, Remington G, Gatley J (2014) Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 48(1):102–110

    Article  PubMed  Google Scholar 

  9. Tsoi DT, Porwal M, Webster AC (2013) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2:CD007253

    PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Evins is supported by NIH Grants R01 DA021245 Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia and K24 DA030443 Mentoring in Addiction Treatment Research.

Conflict of interest

Dr. Evins reports receiving study product and unrestricted research funding support to her institution from EnVivo Pharmaceuticals, GSK and Pfizer. Pfizer is the manufacturer of varenicline. Dr. Hong has received unrestricted research funding from Mitsubishi, Your Energy Systems LLC, and Pfizer. Pfizer is the manufacturer of varenicline. Dr. Kelly reports no potential conflicts.

Author information

Authors and Affiliations

  1. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    A. Eden Evins

  2. University of Maryland School of Medicine, Baltimore, MD, USA

    L. Elliot Hong & Deanna L. Kelly

Authors
  1. A. Eden Evins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Elliot Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deanna L. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Eden Evins.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evins, A.E., Hong, L.E. & Kelly, D.L. T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. Eur Arch Psychiatry Clin Neurosci 265, 269–270 (2015). https://doi.org/10.1007/s00406-014-0556-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0556-y

Keywords

Search

Navigation